Livongo's IPO anniversary. DTx pipelines.

Issue 062.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about two UnitedHealth acquisitions, Bristol Myers Squibb's DTx timeline, and UHG's multiple mulligans in digital diabetes. Here's what's happening this week:

HHS re-re-confirmed yesterday that we are still in a public health emergency because of COVID--19, and this third declaration will also stay in effect for at least yet another 90 days.
Bristol Myers Squibb emailed me last week after the newsletter went out. They asked me to remove the launch timeline for their multiple myeloma digital therapeutic. I found that timeline (Q3 2020 launch) on a (somewhat) blinded job posting for the project, while similar job postings explicitly from BMS didn't provide as many details. BMS said their recruiting firm made a mistake and posted an inaccurate timeline, but wouldn't share the

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Newsletters

Livongo’s IPO anniversary. DTx pipelines.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

Livongo’s IPO anniversary. DTx pipelines.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.